<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23314">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01812213</url>
  </required_header>
  <id_info>
    <org_study_id>NAV4-04</org_study_id>
    <nct_id>NCT01812213</nct_id>
  </id_info>
  <brief_title>Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)</brief_title>
  <acronym>NAV4-04</acronym>
  <official_title>Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Navidea Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Navidea Biopharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate whether [18F]NAV4694 positron emission tomography (PET) scan findings have
      the ability to distinguish subjects with mild cognitive impairment (MCI) who progress to
      Alzheimer's disease (AD) from those who do not.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Incidence of Mild Cognitive Impairment Progression to Alzheimer's Disease</measure>
    <time_frame>3 Years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incidence of Mild Cognitive Impairment Progression to Alzheimer's Disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of [18F]NAV4694 PET Positive scans at 18 months compared to baseline</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incidence of [18F]NAV4694 PET Positive scans  at 18 months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of [18F]NAV4694 PET Positive scans at 36 months compared to baseline</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incidence of [18F]NAV4694 PET Positive scans at 36 months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neuro-cognitive Test Battery Scores at 6 months compared to baseline</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Neuro-cognitive Test Battery Scores at 6 months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neuro-cognitive Test Battery Scores at 12 months compared to baseline</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Neuro-cognitive Test Battery Scores at 12 months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neuro-cognitive Test Battery Scores at 18 months compared to baseline</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Neuro-cognitive Test Battery Scores at 18 months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neuro-cognitive Test Battery Scores at 24 months compared to baseline</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Neuro-cognitive Test Battery Scores at 24 months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neuro-cognitive Test Battery Scores at 30 months compared to baseline</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Neuro-cognitive Test Battery Scores at 30 months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neuro-cognitive Test Battery Scores at 36 months compared to baseline</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Neuro-cognitive Test Battery Scores at 36 months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SUVR scores at 18 months compared to baseline</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in SUVR scores at 18 months compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events post baseline</measure>
    <time_frame>3 Years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of Adverse Events post baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>[18F]NAV4694</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous [18F]NAV4694 (8.1 mCi) administered once every 18 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]NAV4694</intervention_name>
    <arm_group_label>[18F]NAV4694</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has signed informed consent to participate in the study and continues to give
             willing consent for participation

          -  Age â‰¥ 55 years with a diagnosis of MCI

          -  Educational level of at least 6 years

          -  Female subjects will not be of child-bearing potential (&gt; 1 year post-menopausal or
             surgically sterile)

          -  Availability of a &quot;study partner&quot; who can assist in completing rating scales for the
             duration of the study

          -  Cognitive complaints reported by the subject and confirmed by the &quot;study partner&quot;

          -  Clinical Dementia Rating (CDR) global score = 0.5

          -  Mini-mental state examination (MMSE) score of 24-30

          -  Diagnostic and Statistical Manual of Mental Disorders, Version 4, Text Revised
             (DSM-IV-TR) criteria of dementia not fulfilled

        Exclusion Criteria:

          -  Has been previously enrolled in this study and received the investigational product

          -  Has participated in a clinical study involving an investigational pharmaceutical
             product within 30 days prior to screening

          -  Has received anti-amyloid immunotherapy

          -  Has exceeded yearly radioactive dose of 30 mSv

          -  Has a known allergy to the study drug or any of its constituents

          -  Has a history of alcohol abuse or alcohol dependency in the 3 years prior to study
             entry, or is an alcoholic or drug addict, as determined by the investigator

          -  Has ongoing clinically significant (as judged by the investigator), metabolic or any
             other disease that could currently cause impaired memory (e.g., untreated thyroid
             disease, vitamin or other nutritional deficiencies, chronic kidney, or liver disease)

          -  Regular use of psychoactive medications that could affect cognition (e.g.,
             benzodiazepines, sedatives, antipsychotics)

          -  Has received any contrast material (X-ray, MRI) or radiopharmaceutical within 48
             hours prior to, or a therapeutic radiopharmaceutical (e.g., 131I) within 10 days
             prior to, or any radiopharmaceutical administration within 10 radioactive half-lives
             prior to the administration of the investigational product or for whom administration
             of such substances is planned within 7 days after investigational product
             administration

          -  History of major recurrent depressive disorder (per DSM-IV-TR) within the last 5
             years prior to screening

          -  Has a brain tumor or other intracranial lesion, a disturbance of cerebral spinal
             fluid circulation (e.g., normal pressure hydrocephalus), and/or a significant history
             of head trauma or brain surgery

          -  Has signs of major cerebrovascular disease, as verified by medical history and/or
             brain MRI

          -  Is scheduled for surgery and/or another invasive procedure within the 7 days
             following investigational product administration

          -  Has any contraindication to MRI examination, e.g., metal implants, phobia, or cannot
             undergo an MRI for other reasons such as the inability to lie flat

          -  Memory impairment that can be attributed to a disease or condition other than an
             early phase neurodegenerative syndrome

          -  Has a Parkinsonian movement disorder
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cornelia Reininger, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Navidea Biopharmaceuticals Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joanna Shuping</last_name>
    <phone>614-793-7500</phone>
    <phone_ext>162</phone_ext>
    <email>jshuping@navidea.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carley Hartings</last_name>
    <phone>614-793-7500</phone>
    <phone_ext>158</phone_ext>
    <email>chartings@navidea.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Banner Sun Health Research Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Chong</last_name>
      <phone>632-832-8790</phone>
      <email>Christina.Chong@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Marwan Sabbagh, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Galiz Research</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Pedraza</last_name>
      <phone>305-805-0921</phone>
      <email>luisp@galizresearch.com</email>
    </contact>
    <investigator>
      <last_name>Jose Gamez, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Wien Center for Alzheimer's Disease</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsay Pluff</last_name>
      <phone>312-563-4111</phone>
      <email>Lindsay_M_Pluff@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Raj Shah, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Neurosciences Institute</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>SIU School of Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Lokaitis</last_name>
      <phone>217-545-9737</phone>
      <email>blokaitis@siumed.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas A Ala, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Pritchard</last_name>
      <phone>617-855-2649</phone>
      <email>mpritchard1@partners.org</email>
    </contact>
    <investigator>
      <last_name>James M Ellison, M.D., MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qunicy Medical Center, Alzheimer's Disease Center</name>
      <address>
        <city>Quincy</city>
        <state>Massachusetts</state>
        <zip>02169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hayley Brooks</last_name>
      <phone>617-302-6388</phone>
      <email>hayley@thealzcenter.org</email>
    </contact>
    <investigator>
      <last_name>Anil Nair, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurological Associates of Albany</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MaryEllen Torrisi</last_name>
      <phone>518-426-0575</phone>
      <email>research@naaresearch.com</email>
    </contact>
    <investigator>
      <last_name>Richard Holub, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Sollars</last_name>
      <phone>718-405-8363</phone>
      <email>csollars@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Jessica Zwerling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 16, 2014</lastchanged_date>
  <firstreceived_date>March 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild Cognitive Impairment</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
